Celltrion Signs 299.3 Billion KRW Supply Contract for Biosimilar Antibody Drugs
[Asia Economy Reporter Junho Hwang] Celltrion announced on the 29th that it has signed a supply contract for biosimilar antibody drugs (Remsima IV, Truxima, Herzuma, Vegzelma) with its affiliate Celltrion Healthcare. The contract amount is 299.3 billion KRW, which corresponds to 15.66% of the sales in 2021. The contract period is until the 30th of this month.
Hot Picks Today
"Buy on Black Monday"... Japan's Nomura Forecasts 590,000 for Samsung, 4 Million for SK hynix
- "Plunged During the War, Now Surging Again"... The Real Reason Behind the 6% One-Day Silver Market Rally [Weekend Money]
- "Not Everyone Can Afford This: Inside the World of the True Top 0.1% [Luxury World]"
- "We're Now Earning 10 Million Won a Month"... Semiconductor Boom Drives Performance Bonuses at Major Electronic Component Firms
- Experts Are Already Watching Closely..."Target Stock Price 970,000 Won" Now Only the Uptrend Remains [Weekend Money]
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
